AAV-mediated genome targeting of the GLA cDNA in newborn and juvenile Gla KO mice achieves long-term correction of Fabry disease
Molecular Therapy Advances · 2026-12 · 34 (4) · 201864
DOI: 10.1016/j.omta.2026.201864 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Advances, 2026-12. Verfasst von Himanshi Saxena und 12 weiteren Autor:innen. Beteiligte Einrichtung: International Centre for Genetic Engineering and Biotechnology, Padriciano, 99, 34149 Trieste, Italy. Die Arbeit nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Telethon Foundation.
Abstract (Originalsprache)
Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the GLA gene, resulting in deficient α-galactosidase A (α-Gal A) activity and progressive substrate accumulation in multiple organs. Current enzyme replacement therapies are limited by short enzyme half-life, immunogenicity, and high costs, underscoring the need for durable treatments, particularly in the context of newborn screening programs that enable early diagnosis. Here, we employed AAV-mediated genome targeting to insert a promoter-less codon-optimized human GLA cDNA into the albumin locus of Fabry mice, with homologous recombination enhanced by SaCas9 nuclease or fludarabine. This approach permanently modifies the hepatocyte genomes, converting them into bio-factories that secrete α-Gal A, which is then captured by organs expressing mannose-6-phosphate receptors, reducing glycosphingolipid accumulation in affected tissues. In fact, treatment of newborn and juvenile mice resulted in sustained supraphysiological α-Gal A activity, complete or near-complete clearance of lyso-Gb3 in plasma and target tissues, and prevention of neuropathic deficits, as assessed by the hot-plate test. These findings demonstrate that hepatocyte genome editing can provide a one-time, long-lasting therapeutic strategy for FD, potentially applicable across diverse GLA mutations and suitable for early intervention in patients identified through newborn screening, aiming at improving patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- International Centre for Genetic Engineering and Biotechnology, Padriciano, 99, 34149 Trieste, Italy.
- Institute of Clinical Pathology, Department of Laboratory Medicine, University Hospital of Udine, P. Le Santa Maria Della Misericordia 15, 33100 Udine, Italy.
- Regional Coordinator Centre for Rare Diseases, University Hospital of Udine, P. Le Santa Maria Della Misericordia 15, 33100 Udine, Italy.
Förderung
- Telethon Foundation
Zitieren
APA
Saxena, H., Romano, G., Domenis, R., Biasizzo, J., Ferro, M., Ferino, D., Vicidomini, A., Colliva, A., Iaconcig, A., Bortolussi, G., Zentilin, L., Dardis, A., & Muro, A. F. (2026). AAV-mediated genome targeting of the GLA cDNA in newborn and juvenile Gla KO mice achieves long-term correction of Fabry disease. Molecular Therapy Advances, 34(4), 201864. https://doi.org/10.1016/j.omta.2026.201864
Vancouver
Saxena H, Romano G, Domenis R, Biasizzo J, Ferro M, Ferino D, et al. AAV-mediated genome targeting of the GLA cDNA in newborn and juvenile Gla KO mice achieves long-term correction of Fabry disease. Molecular Therapy Advances. 2026;34(4):201864. doi:10.1016/j.omta.2026.201864
BibTeX
@article{Saxena2026,
author = {Saxena, Himanshi and Romano, Giulia and Domenis, Rossana and Biasizzo, Jessica and Ferro, Martina and Ferino, Dania and Vicidomini, Antonio and Colliva, Andrea and Iaconcig, Alessandra and Bortolussi, Giulia and Zentilin, Lorena and Dardis, Andrea and Muro, Andrés F},
title = {AAV-mediated genome targeting of the GLA cDNA in newborn and juvenile Gla KO mice achieves long-term correction of Fabry disease},
journal = {Molecular Therapy Advances},
year = {2026},
volume = {34},
number = {4},
pages = {201864},
doi = {10.1016/j.omta.2026.201864}
}
EUVIMED